Sage Journals: Discover world-class research

Abstract

Using rats fed 22 g/d of a control diet containing 0.005% zinc (Zn) or 2 Zn-excess diets containing 0.05% or 0.2% Zn for 4 weeks, we examined the mechanisms involved in the deterioration of renal function induced by Zn-excess intake. An increase in Zn intake elevated mean blood pressure (BP) and reduced renal blood flow (RBF) and inulin clearance in a dose-dependent manner. This decline in inulin clearance may be derived from a fall in RBF. Administration of the nitric oxide (NO) synthase inhibitor, N^ω-nitro-l-arginine methyl ester, markedly increased mean BP and significantly decreased RBF in the 3 groups of rats. Administration of the exogenous superoxide radical (OO⁻) scavenger, tempol, significantly decreased mean BP and substantially increased RBF in all groups of rats. These observations suggest that both an elevation in systemic BP and a reduction in RBF seen in the 2 Zn-excess diet groups result from a decrease in the action of the vasodilator, NO, through the formation of peroxynitrite based on the nonenzymatic reaction of NO and increased OO⁻. Indeed, the activity of the endogenous OO⁻ scavenger, copper/Zn-superoxide dismutase, was significantly reduced in the vessel wall of rats fed 2 Zn-excess diets versus a control diet. 8-Hydroxy-2′-deoxyguanosine formation caused by OO⁻ generation was notably elevated in the kidneys of rats fed 2 Zn-excess diets relatively to rats fed a control diet. Thus, Zn-excess intake leads to the aggravation of renal function concomitantly with an increase in systemic BP predominantly through the oxidative stress caused by OO⁻.

Keywords

zinc blood pressure renal function oxidative stress

Introduction

The transition metal, zinc (Zn), is an essential trace element in humans and animals.^1
–3 Nutritional Zn deficiency leads to the disorder of the skin epithelium, the gastrointestinal system, the reproductive system, the neural system, the endocrine system, the ocular system, and the immune system.^1
–3 In recent years, Zn tablets and Zn-supplemented food have been circulating in Japan, the United States, and Europe for the purpose of maintaining good health and promoting health.³ Moreover, oral Zn therapy has been recently done to treat hypogeusia and decubitus ulcers in adults³ and hypogonadism and growth retardation from infants to adolescents.^4,5 Nevertheless, Zn toxicity resulting from Zn-excess intake has not been fully understood.

The vasodilatory gas, nitric oxide (NO), is primarily produced by endothelial nitric oxide synthase (NOS) from the terminal guanidino nitrogen of l-arginine in vascular endothelial cells.^6,7 Nitric oxide participates in the regulation of vascular tone in the vessel wall via the soluble guanylate cyclase-mediated signaling pathway.⁶ Evidence of interest^8
–10 has been recently accumulated that NO nonenzymatically reacts with superoxide radical (OO⁻) in the vessel wall, consequently resulting in a decrease in the vasodilatory action of NO through the formation of peroxynitrite (ONOO⁻).

The endogenous OO⁻ scavenger, copper (Cu)/Zn-superoxide dismutase (SOD), is an enzyme requiring both Cu and Zn for exhibiting the function.^1,3 Ordinarily, the activity of Cu/Zn-SOD is reduced in either a Zn-deficient or a Cu-deficient state, or both.¹ Recently, Cu/Zn-SOD has been reported to have a protective effect on the oxidative stress induced by OO⁻ through the OO⁻ scavenging ability.^3,11

–14 Thus, Cu/Zn-SOD may have a central role in defending the vessel wall against OO⁻-induced oxidative stress.^15,16

Our previous studies revealed that Zn-excess intake led to an elevation in systemic blood pressure (BP)¹⁷ and a reduction in renal blood flow (RBF) and inulin clearance.¹⁸ The major mechanisms responsible for a rise in systemic BP may have been due to an increase in the action of OO⁻ in the vessel wall and the resultant decrease in the action of the vasodilator, NO, resulting from the formation of ONOO⁻.¹⁷ The increase in the action of OO⁻ appeared to be attributed to a fall in the activity of Cu/Zn-SOD caused in the vessel wall by Cu deficiency secondary to Zn-excess intake.¹⁷ By now, the mechanisms involved in a decrease in RBF and inulin clearance caused by Zn-excess intake remain unclear, however.

The present study was designed to explore the mechanisms responsible for the deterioration of renal function caused by Zn-excess intake. Thus, we examined basal systolic BP, diastolic BP, RBF, and inulin clearance in rats fed a control diet containing 0.005% Zn or 2 Zn-excess diets containing 0.05% or 0.2% Zn for 4 weeks. Concomitantly, we analyzed mean BP and RBF before and after administration of the NOS inhibitor, N^ω-nitro-l-arginine methyl ester (l-NAME), or the membrane-permeable SOD mimetic compound, 4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl (tempol), in the 3 groups of rats. Moreover, we measured the activity of Cu/Zn-SOD in the thoracic aorta to disclose a potential source responsible for augmenting the action of OO⁻. In addition, we determined the levels of 8-hydroxy-2′-deoxyguanosine (8-OHdG), an oxidative stress marker, in the kidneys to confirm an actual increase in OO⁻ production.

Materials and Methods

Chemicals and Reagents

Tempol, thiobutabarbital, inulin, nuclease P₁, and a DNA Extractor WB Kit were purchased from Wako Pure Chemicals (Osaka, Japan). Alkaline phosphatase was obtained from Toyobo Co, Ltd (Osaka, Japan). The l-NAME was supplied by Research Biochemicals International (Natick, Massachusetts). A highly sensitive 8-OHdG Check enzyme-linked immunosorbent assay (ELISA) kit was obtained from Japan Institute for the Control of Aging (Shizuoka, Japan). Other chemicals were of analytical grade.

Dietary Regimen

Male Sprague-Dawley rats (n = 117) weighing approximately 150 to 170 g were obtained from Clea Japan Inc. (Tokyo, Japan). The rats were not specific pathogen-free animals. Prior to dietary intervention, all rats were preconditioned with a control diet containing 0.005% Zn for 1 week. Following preconditioning, the rats (approximately 180-210 g) were divided at random and in turns into 3 groups and given 22 g/d of a control diet (1.1 mg Zn/d) or 2 Zn-excess diets containing 0.05% Zn (11 mg Zn/d) or 0.2% Zn (44 mg Zn/d) for 4 weeks. The rats were allowed to have free access to double filtered deionized water during the overall experimental period. Consequently, the quantity of Zn ingested for 4 weeks amounted to approximately 31 mg Zn/rat in the control diet group, approximately 308 mg Zn/rat in the 0.05% Zn-excess diet group and approximately 1232 mg Zn/rat in the 0.2% Zn-excess diet group. Dietary compositions such as protein, carbohydrates, fat, minerals, and vitamin mixtures were identical except for Zn content in the 3 diets.^17,19 The food consumption was monitored daily during the dietary conditioning. The quantity of diet ingested was comparable in the 3 groups of rats. Body weight was measured immediately before the start of dietary manipulation (week 0) and monitored at an interval of a week up to the termination of dietary treatment. All animal experiments were performed in accordance with the Animal Experiments Guidelines of the Jikei University School of Medicine and Saitama Medical University.

Blood Collection and Tissue Preparations

Following dietary manipulation, the abdominal cavity of rats was opened under light ether anesthesia. Blood was then collected from the bifurcation of the aorta for the measurements of serum Zn and Cu using an atomic absorption spectrophotometer (Shimadzu, Kyoto, Japan).^17,19 Subsequently to blood collection, the thoracic aorta and kidneys were perfused with phosphate-buffered saline through the bifurcation of aorta^14,17,20 and immediately excised. The surrounding connective tissue was removed from the thoracic aorta and stored at −80°C for the subsequent analysis of Cu/Zn-SOD activity.^14,17 The kidneys were immediately decapsulated and longitudinally sliced into half. A sliced preparation was then fixed at 4°C overnight with 4% paraformaldehyde dissolved in phosphate-buffered saline and mounted in paraffin blocks for the subsequent hematoxylin–eosin (H&E) staining.^19,20 The remainder was stored at −80°C to measure the levels of 8-OHdG.²¹

Measurements of Systemic BP and RBF

Following dietary conditioning, rats were intraperitoneally anesthetized with 125 mg/kg of thiobutabarbital and maintained at 37°C on a warmed rodent operating table. PE-50 Polyethylene catheters (Becton Dickson, Spark, Maryland) filled with heparinized saline were then placed around the femoral vein and the abdominal aorta via the femoral artery. Systolic BP, diastolic BP, and mean BP were measured through the placed arterial catheter connected to a Nihon Koden pressure transducer (Tokyo, Japan) according to the method reported previously.^12,14,17,18 Subsequently, the left kidney was exposed via midabdominal incision. The renal artery was then dissected carefully from the renal vein and fitted with a perivascular flow probe (internal diameter 1.0 mm) connected to an ultrasonic flowmeter (PD-20; Crystal Biotech, Northborough, Massachusetts) to measure RBF.^12,18 The pressure transducer and flowmeter were connected to a personal computer with a MacLab System (ADInstruments, Sydney, New South Wales, Australia) for simultaneous recording of BP and RBF.^12,14,17,18 Following surgery, intravenous infusion of saline was performed at 2 mL/h through the placed venous catheter to maintain a euvolemic state.^12,14,17,18 The experimental procedure was as follows.

Experiment 1

Rats subjected to surgery were left on a warmed rodent operating table for approximately 60 minutes until BP levels reached a steady state. Basal systolic BP, diastolic BP, mean BP, and RBF levels were then recorded for 30 minutes. Subsequently, changes in mean BP and RBF levels after suppressing the biosynthesis of the vasodilator, NO, were examined for 30 minutes by injecting 10 mg/kg of the NOS inhibitor, l-NAME,^12,14,17 dissolved in saline through the placed venous catheter.

Experiment 2

Using another group of rats, changes in mean BP and RBF levels after scavenging OO⁻ were explored for 30 minutes following the measurements of basal mean BP and RBF levels by treating with 5 mg/kg/min of the OO⁻ scavenger, tempol,^12,14,17 dissolved in saline through the venous catheter placed.

Analysis of Inulin Clearance

Inulin clearance was evaluated in rats fed a control diet or 2 Zn-excess diets as described previously.^12,18 Rats were anesthetized with 125 mg/kg of thiobutabarbital and placed on a heating pad. Modified PE-10 polyethylene catheters were inserted into the left femoral artery for blood collection and into the left femoral vein for constant infusion (5 μL/min) of inulin dissolved in saline (5 mg/mL). The PE-10 polyethylene catheters were also inserted into the bilateral ureters, exposed via a midabdominal incision, for urinary collection. Rats were left for 4 hours to allow the serum inulin concentration and urinary inulin excretion rate to stabilize. Blood (300 μL) was then collected, and urine was stored for the next hour, followed by the collection of blood again. A commercially available inulin assay kit was used for the measurements of inulin concentrations in the sera and urine (Toyobo). The concentrations of inulin in the sera, obtained before and after urine collection, were measured and averaged for each rat. Inulin clearance was calculated from the average serum concentration of inulin, urinary concentration of inulin, urine volume, and the weight of the kidneys.

Assay of Cu/Zn-SOD Activity

The activity of Cu/Zn-SOD was measured according to the method reported previously.^14,17 The thoracic aorta excised was suspended in ice-cold 25 mmol/L Tris-HCl, pH 7.4, containing 1 mmol/L dithiothreitol, 10 U/mL trazyrol, 1% leupeptin, and 10 mmol/L phenylmethylsulfonyl fluoride. Homogenization was then carried out 3 times for 10 seconds each with sonication. An organic solution of ethanol/chloroform (62.5/37.5, v/v) was added to the homogenates for the extraction of Cu/Zn-SOD (this procedure concomitantly inactivates manganese SOD). The samples were vortexed vigorously and centrifuged at 3000g for 5 minutes at 4°C. The aqueous layer of the samples containing Cu/Zn-SOD was collected for the measurements of Cu/Zn-SOD activity. The activity of Cu/Zn-SOD was determined according to the protocol provided by OXIS Health Products, Inc (Portland, Oregon) by measuring at 525 nm the optical density of a chromophore generated by the SOD-mediated autoxidation of the substrate 5,6,6a,11-tetrahydro-3,9,10-trihydroxybenzo[c]-fluorine.^14,17

Assay of 8-OHdG Content

The extraction of DNA from 100 mg of sliced kidney tissues was conducted according to the protocol provided by Wako Pure Chemicals using a DNA Extractor WB Kit.²¹ After DNA extraction, 200 µg of DNA in Tris-EDTA buffer consisting of 10 mmol/L Tris-HCl, pH 8.0 and 1 mmol/L EDTA, pH 8.0 was hydrolyzed by adding both 15 µL of 200 mmol/L sodium acetate, pH 4.8 and 15 µL of nuclease P₁ at a concentration of 1 mg/mL. Following incubation at 37°C for 1 hour, 15 µL of 1 mmol/L Tris-HCl, pH 7.4 and 7 µL of alkaline phosphatase at a concentration of 200 unit/0.7 mL were added and further incubated at 37°C for 1 hour. The DNA hydrolysates were processed for deproteinization by ultrafiltration with a Microcon YM-10 filter (Millipore, Massachusetts).²¹ The concentrations of 8-OHdG were analyzed by a highly sensitive 8-OHdG Check ELISA kit.²¹

Statistical Analysis

Data reported are expressed as means ± standard deviations of the values obtained from 7 to 9 rats. Statistical analysis was based on Duncan multiple range comparison test, 1-way analysis of variance (ANOVA) with Student t-test, or 2-way ANOVA with Student t-test. A value of P < 0.05 was considered statistically significant.

Results

Table 1 presents changes in body weight of rats fed a control diet (n = 9) or 2 Zn-excess diets (n = 9 each) for 4 weeks. Rats fed a control diet gain in weight from 191.1 ± 6.0 to 291.5 ± 17.0 g for 4 weeks. Similarly, rats fed 0.05% and 0.2% Zn-excess diets gain in weight from 196.9 ± 9.0 to 277.6 ± 12.5 g and from 192.1 ± 5.1 to 280.4 ± 10.9 g, respectively, for 4 weeks. The 3 groups of rats showed a progressive gain in body weight for 4 weeks following the initiation of dietary conditioning (P < 0.005; weeks 2-4 vs week 0). No significant differences in body weight during the dietary manipulation were observed among the 3 groups of rats, however.

Table 1.

Body Weight of Rats Fed a Control Diet or 2 Zn-Excess Diets for 4 Weeks.^a

	0	1	2	3	4
Control diet	191.1 ± 6.0	199.3 ± 14.0	228.9^b ± 21.1	263.7^b ± 14.4	291.5^b ± 17.0
0.05% Zn diet	196.9 ± 9.0	200.9 ± 5.0	227.9^b ± 15.5	257.3^b ± 18.4	277.6^b ± 12.5
0.2% Zn diet	192.1 ± 5.1	191.2 ± 12.1	220.6^b ± 11.3	249.6^b ± 7.6	280.4^b ± 10.9

Abbreviations: SD, standard deviation; Zn, zinc.

^a Changes in rat body weight (g) during isocaloric feeing of a control diet or 2 Zn-excess diets for 4 weeks. Body weight was measured immediately before the start of dietary manipulation (week 0) and at 1, 2, 3, and 4 weeks after the initiation of dietary treatment. Data reported represent means ± SDs of the values obtained from 9 rats in each group. Intragroup comparison was based on Duncan multiple range comparison test.

^b P < 0.005 compared to each value obtained at week 0.

Table 2 shows the levels of serum Zn, Cu, and the Cu/Zn ratio in rats fed a control diet (n = 8) or 2 Zn-excess diets (n = 8 each) for 4 weeks. Levels of serum Zn, serum Cu, and the Cu/Zn ratio were 105.5 ± 6.4 μg/dL, 123.6 ± 7.8 μg/dL, and 1.171 ± 0.095, respectively, in rats fed a control diet. Similarly, levels of serum Zn, serum Cu, and the Cu/Zn ratio were 133.2 ± 11.7 μg/dL, 98.1 ± 7.1 μg/dL, and 0.736 ± 0.056, respectively, in rats fed a 0.05% Zn-excess diet and 286.3 ± 25.3 μg/dL, 14.4 ± 1.07 μg/dL, and 0.050 ± 0.003, respectively, in rats fed a 0.2% Zn-excess diet. Rats fed 0.05% and 0.2% Zn-excess diets had significantly increased concentrations of serum Zn by 1.3 and 2.7 times, respectively, relative to rats fed a control diet (P < 0.005). Inversely, rats fed 0.05% and 0.2% Zn-excess diets exhibited markedly decreased concentrations of serum Cu by 21% and 88%, respectively, when compared to rats fed a control diet (P < 0.005). Consequently, the Cu/Zn ratio was profoundly lower by 37% and 96% in rats fed 0.05% and 0.2% Zn-excess diets, respectively, than in rats fed a control diet (P < 0.005).

Table 2.

Levels of Serum Zn and Cu and the Cu/Zn Ratio in Rats Fed a Control Diet or 2 Zn-Excess Diet for 4 Weeks.^a

	Zn	Cu	Cu/Zn
Control diet	105.5 ± 6.4	123.6 ± 7.8	1.171 ± 0.095
0.05% Zn diet	133.2 ± 11.7^b	98.1 ± 7.1^b	0.736 ± 0.056^b
0.2% Zn diet	286.3 ± 25.3^b	14.4 ± 1.07^b	0.050 ± 0.003^b

Abbreviations: Zn, zinc; Cu, copper; SD, standard deviation.

^a Levels of serum Zn (μg/dL) and Cu (μg/dL) were measured at the termination of dietary manipulation for 4 weeks. Data reported are means ± SDs of the values obtained from 8 rats in each group. Intergroup comparisons were based on 1-way analysis of variance with Student t-test.

^b P < 0.005 compared to each value obtained from the control diet group.

Figure 1 shows basal BP (A) and renal function (B) levels obtained from rats fed a control diet (n = 7) or 2 Zn-excess diets (n = 7 each) for 4 weeks. An increase in Zn intake augmented basal systolic BP, diastolic BP, and mean BP levels (P < 0.05) and decreased basal RBF and inulin clearance levels (P < 0.01) in a dose-dependent manner.

Figure 1.

Basal blood pressure (mm Hg) levels (A) and basal renal blood flow (arbitrary units) and inulin clearance (mL/min/g kidney weight) levels (B) observed in rats fed a control diet or 2 Zn-excess diets for 4 weeks. Blood pressure, renal blood flow, and inulin clearance were measured at 4 weeks after the start of dietary treatment. Data reported represent means ± standard deviations (SDs) of the values obtained from 7 rats in each group. Statistical analysis was based on 1-way analysis of variance with Student t-test.

Figure 2 exhibits the effects of the NOS inhibitor, l-NAME, on mean BP (A) and RBF (B) levels obtained from rats fed a control diet (n = 7) or 2 Zn-excess diets (n = 7 each) for 4 weeks. Basal mean BP and RBF levels in each group of rats that were not treated with l-NAME were similar to the results of Figure 1. l-NAME treatment significantly increased the mean BP levels (P < 0.005) and markedly reduced the RBF levels (P < 0.01) in the 3 groups of rats. There were no significant differences in mean BP and RBF levels among the 3 groups of rats that were treated with l-NAME. However, a decrease in RBF levels tended to be more prominent in rats fed 2 Zn-excess diets than in rats fed a control diet.

Figure 2.

Effects of l-NAME treatment on mean blood pressure (mm Hg) levels (A) and renal blood flow (arbitrary units) levels (B) observed in rats fed a control diet or 2 Zn-excess diets for 4 weeks. Data reported represent means ± standard deviations (SDs) of the values obtained from 7 rats in each group. Statistical analysis was based on 2-way analysis of variance with Student t-test. White bars, basal condition groups. Black bars, l-NAME treatment groups. l-NAME indicates N^ω-nitro-l-arginine methyl ester.

Figure 3 shows the effects of the OO⁻ scavenger, tempol, on mean BP (A) and RBF (B) levels obtained from rats fed a control diet (n = 8) or 2 Zn-excess diets (n = 8 each) for 4 weeks. Basal mean BP and RBF levels in each group of rats with no tempol treatment were comparable to the results of Figure 1. Tempol treatment significantly decreased the mean BP levels (P < 0.01) and substantially increased the RBF levels (P < 0.05) in the 3 groups of rats. No significant differences in mean BP and RBF levels were noted among the 3 groups of rats with tempol treatment. However, an increase in RBF levels tended to be blunted in rats fed 2 Zn-excess diets, particularly a 0.2% Zn-excess diet, versus a control diet.

Figure 3.

Effects of tempol treatment on mean blood pressure (mm Hg) levels (A) and renal blood flow (arbitrary units) levels (B) observed in rats fed a control diet or 2 Zn-excess diets for 4 weeks. Data reported represent means ± standard deviations (SDs) of the values obtained from 8 rats in each group. Statistical analysis was based on 2-way analysis of variance with Student t-test. White bars, basal condition groups. Black bars, tempol treatment groups.

Figure 4 presents representative photomicrographs of the H&E-stained kidney sections obtained from rats fed a control (A) or a 0.2% Zn-excess (B) diet for 4 weeks. The H&E staining revealed no significant morphologic changes in glomeruli, tubules, the interstitium, and vessels of the kidney from rats fed a 0.2% Zn-excess versus a control diet. This indicates that the kidney is structurally intact in rats fed a 0.2% Zn-excess diet for 4 weeks.

Figure 4.

Representative photomicrographs of the hematoxylin–eosin-stained kidney sections obtained from rats fed a control (A) or a 0.2% Zn-excess (B) diet for 4 weeks. No significant pathological findings in glomeruli, tubules, the interstitium, and vessels were seen in the kidney of rats fed a 0.2% Zn-excess versus a control diet. Magnification: ×100.

Table 3 shows the activities of Cu/Zn-SOD obtained from the thoracic aorta of rats fed a control diet (n = 8) or 2 Zn-excess diets (n = 8 each) for 4 weeks. The activities of Cu/Zn-SOD (U/mg protein) were 32.6 ± 2.9, 24.2 ± 1.8, and 8.3 ± 0.7 in rats fed a control, 0.05% Zn-excess, and 0.2% Zn-excess diets, respectively. The activities of Cu/Zn-SOD was significantly diminished by 26% and 75% in rats fed 0.05% and 0.2% Zn-excess diets, respectively, relative to rats fed a control diet.

Table 3.

Activities of Cu/Zn-Superoxide Dismutase in the Thoracic Aorta of Rats Fed a Control Diet or 2 Zn-Excess Diets for 4 Weeks.^a

Control diet	32.6 ± 2.9
0.05% Zn diet	24.2 ± 1.8^b
0.2% Zn diet	8.3 ± 0.7^b

Abbreviations: Cu, copper; Zn, zinc; SD, standard deviation.

^a Activities of Cu/Zn-superoxide dismutase (U/mg protein) in the thoracic aorta were measured at the end of dietary treatment for 4 weeks. Data reported are means ± SDs of the values obtained from 8 rats in each group. Intergroup comparisons were based on 1-way analysis of variance with Student t-test.

^b P < 0.005 compared to the value obtained from the control diet group.

Table 4 presents the levels of 8-OHdG obtained from the kidneys of rats fed a control diet (n = 8) or 2 Zn-excess diets (n = 8 each) for 4 weeks. Levels of 8-OHdG (ng/μg DNA) were 1.9 ± 0.2, 2.6 ± 0.3, and 4.8 ± 0.6 in rats fed a control, 0.05% Zn-excess, and 0.2% Zn-excess diets, respectively. Levels of 8-OHdG were elevated according to an increase in Zn intake. Particularly, levels of 8-OHdG were significantly augmented by 2.5 times in rats fed a 0.2% Zn-excess diet when compared to rats fed a control diet.

Table 4.

Levels of 8-OHdG in the Kidneys of Rats Fed a Control Diet or 2 Zn-Excess Diets for 4 Weeks.^a

Control diet	1.9 ± 0.2
0.05% Zn diet	2.6 ± 0.3
0.2% Zn diet	4.8 ± 0.6^b

Abbreviations: 8-OHdG, 8-hydroxy-2′-deoxyguanosine; Zn, zinc; SD, standard deviation.

^a Levels of 8-OHdG (ng/μg DNA) in the kidneys were measured at the end of dietary treatment for 4 weeks. Data reported are means ± SDs of the values obtained from 8 rats in each group. Intergroup comparisons were based on 1-way analysis of variance with Student t-test.

^b P < 0.005 compared to the value obtained from the control diet group.

Discussion

There is a reciprocal relationship between the intestinal absorption rates of Zn and Cu.^1,3,22,23 The ingestion of a diet containing large amounts of Zn augments intestinal absorption of Zn²⁺ instead of Cu²⁺.^1,3,22
–24 This increased absorption of Zn²⁺ leads to the replacement of serum Cu with serum Zn, resulting in a fall in the Cu/Zn ratio characteristic in a Zn-excess state.^1,3,22
–24 Indeed, the present study demonstrated an increase in serum Zn concentrations, a decrease in serum Cu concentrations, and a reduction in the Cu/Zn ratio according to the augmentation in Zn ingestion (Table 2). These observations indicate that rats fed Zn-excess diets may not only be in a Zn-excess state but also in a Cu-deficient state secondary to Zn-excess intake.

Of interest in the present study was that rats fed 2 Zn-excess diets had a dose-dependent increase in basal systolic BP, diastolic BP, and mean BP levels and a dose-dependent decrease in basal RBF and inulin clearance levels relative to rats fed a control diet (Figure 1). These observations indicate an elevation in basal systemic BP levels and a reduction in basal renal function due to Zn-excess ingestion. The fall in inulin clearance seen in rats fed 2 Zn-excess diets may be the result of a reduction in RBF because H&E staining showed no significant morphologic changes in the kidneys obtained from rats fed a 0.2% Zn-excess diet (Figure 4).

The family of NOS produces the vasodilatory gas, NO, from the terminal guanidino nitrogen of l-arginine through the oxidative effect.^6,7 Nitric oxide participates in the regulation of systemic BP and RBF via the modulation of vascular tone.^10,12 Actually, intravenous injection of the NOS inhibitor, l-NAME, elevated mean BP levels and reduced RBF levels in rats fed a control diet and 2 Zn-excess diets (Figure 2). The mean BP levels elevated and the RBF levels reduced were comparable among the 3 groups of rats. These observations suggest the involvement of NO in the regulation of systemic BP and RBF in the 3 groups of rats. Therefore, the vasodilator, NO, may play a role in suppressing an elevation in systemic BP and a fall in renal function in the Zn-excess setting.

We^12,14,17 and others^8
–10 have recently reported that an increase in the action of OO⁻ in the vessel wall causes a reduction in the action of the vasodilator, NO, through the formation of ONOO⁻. We demonstrated in the present study that intravenous administration of the exogenous OO⁻ scavenger, tempol, caused a fall in mean BP levels and a rise in RBF levels in rats fed a control diet and 2 Zn-excess diets (Figure 3). In a previous study, we obtained similar results on tempol treatment for an increase in systemic BP caused by Zn-excess intake.¹⁷ These observations indicate that OO⁻ may be a modifier of renal function as well as systemic BP via a decrease in the action of the vasodilator, NO, based on the formation of ONOO⁻ in rats fed 2 Zn-excess diets. Thus, the mechanisms responsible for an elevation in systemic BP and the deterioration of renal function in rats fed 2 Zn-excess diets may be due to an increase in the action of OO⁻ in the vessel wall. Indeed, an increase in 8-OHdG formation caused by enhanced OO⁻ production was seen in rats fed 2 Zn-excess diets (Table 4).

There were no significant differences in mean BP and RBF levels after l-NAME or tempol treatment among rats fed a control diet and 2 Zn-excess diets (Figures 2 and 3). Mean BP levels obtained from rats fed 2 Zn-excess diets were essentially comparable to those obtained from rats fed a control diet (Figures 2A and 3A). However, RBF levels obtained from rats fed 2 Zn-excess diets were slightly different from those obtained from rats fed a control diet (Figures 2B and 3B). There is a possibility that in addition to both NO and OO⁻, some vasoconstrictive factor takes part in the modulation of RBF levels in the Zn-excess settings. We have recently found a significant and dose-dependent increase in the potent vasoconstrictor, angiotensin II, in the kidneys of rats fed 2 Zn-excess diets when compared to those of rats fed a control diet.¹⁸ This increased angiotensin II may be in part related to an alteration in RBF levels observed in Zn-excess ingestion.

The vasodilator, NO, augments glomerular capillary plasma flow (Q_A) and single nephron glomerular filtration rate (SNGFR) via a decrement in afferent arteriole resistance due to afferent arteriole vasodilation and an increment in the ultrafiltration coefficient (Kf) due to mesangial cell relaxation.^25,26 The present study, therefore, indicates that a fall in inulin clearance observed in rats fed 2 Zn-excess diets may be attributed to a decline in SNGFR derived from a decrement in Q_A caused by both an increment in afferent arteriole resistance due to an increase in afferent arteriole vasoconstriction and a decrement in Kf due to mesangial cell contraction through a decrease in the action of the vasodilator, NO.

On the other hand, the vasoconstrictor, angiotensin II, reduces Q_A and SNGFR through an increment in glomerular arteriole resistance due to afferent and efferent arteriole vasoconstriction (afferent arteriole < efferent arteriole) and a decrement in Kf due to mesangial cell contraction.^25,26 If the vasoconstrictor, angiotensin II, is in part involved, it is a conceivable that angiotensin II also contributes to a decline in SNGFR through a fall in Q_A due to both an increment in glomerular arteriole resistance and a decrement in Kf in rats fed 2 Zn-excess diets.

The endogenous OO⁻ scavenger, Cu/Zn-SOD, dismutases OO⁻ to hydrogen peroxide and the hydrogen peroxide is converted into water by catalase and glutathione peroxidase.^21,27 The Cu/Zn-SOD requiring both Cu and Zn for exhibiting the function is an endogenous enzyme scavenging OO⁻ in the vessel wall.^1,3 It is therefore considered that Cu/Zn-SOD plays a central role in defending the vessel wall against the oxidative stress caused by OO⁻. In the present (Table 3) and previous¹⁷ studies, the activity of Cu/Zn-SOD in the thoracic aorta was significantly reduced in rats fed 2 Zn-excess diets relative to rats fed a control diet in a dose-dependent manner. This fall in the activity of Cu/Zn-SOD may be due to the effect of Cu deficiency secondary to Zn-excess ingestion, contributing to an increase in the action of OO⁻ in the vessel wall of rats fed 2 Zn-excess diets.

Values for both systemic BP and renal function observed in rats fed a 0.05% Zn-excess diet (11 mg Zn/d) were at the borderline in statistical significance when compared to those obtained from rats fed a control diet (1.1 mg Zn/d), suggesting that the lowest observed adverse effect level of Zn is approximately 11 mg/d (Figure 1).

Taneja and Mandal reported that an increase in serum Zn levels and a decrease in serum Cu levels were observed in the patients with hypertension versus the normotensive individuals in the Chandigarh of India.^28,29 Serum Zn and Cu levels were 0.177 ± 0.01 and 0.063 ± 0.01 mg/dL, respectively, in the normotensive subjects and 0.46 ± 0.01 and 0.035 ± 0.01 mg/dL, respectively, in the hypertensive subjects. The Cu/Zn ratio was approximately 0.36 and 0.076 in the normotensive and the hypertensive subjects, respectively. The hypertensive subjects had significantly higher serum Zn levels by 2.6 times than the normotensive subjects (2.7 times increase in rats fed a 0.2% Zn-excess vs a control [0.005% Zn] diet in the present study). Inversely, serum Cu levels were profoundly reduced by 44.4% in the hypertensive subjects when compared to the normotensive subjects (88% fall in rats fed a 0.2% Zn-excess versus a control diet in the present study). Consequently, the Cu/Zn ratio was notably decreased by 78.6% in the hypertensive subjects relative to the normotensive subjects (96% fall in rats fed a 0.2% Zn-excess versus a control diet in the present study). These observations, particularly the increase rate of serum Zn levels and the decrease rate of the Cu/Zn ratio in the hypertensive versus the normotensive subjects, were similar to those obtained in the present study (Table 2). Thus, the 3 dietary settings, a control diet containing 0.005% Zn and 2 Zn-excess diets containing 0.05% Zn or 0.2% Zn, used in the present study may be available to producing the Zn-excess animal models similar to humans.

In summary, the present study demonstrated that Zn-excess intake caused the deterioration of renal function via an increase in the action of OO⁻. Zn-excess intake may be a critical factor to elevate systemic BP and to reduce renal function through the oxidative stress caused by OO⁻. A reduction in the activity of Cu/Zn-SOD concomitantly seen in the vessel wall appeared to participate in the increase in the action of OO⁻. Indeed, 8-OHdG formation caused by OO⁻ generation was substantially elevated in the Zn-excess setting. Hereafter, detailed epidemiologic studies should be done to elucidate the relationship between renal hemodynamics/function and Zn-excess intake in humans.

Footnotes

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship and/or publication of this article: This work was supported by Grants (No. 21590715) for Scientific Research from the Ministry of Education, Science, Sports and Culture of Japan.

References

Vallee

Falchuk

. The biochemical basis of zinc physiology. Physiol Rev. 1993;73(1):79–118.

Yanagisawa

Nodera

. Zinc physiology and clinical practice. Biomed Res Trace Elements. 2007;18(1):3–9.

Yanagisawa

. Zinc deficiency and clinical practice—validity of zinc preparations. Yakugaku Zasshi. 2008;128(3):333–339.

Allen

. Zinc and micronutrient supplements for children. Am J Clin Nutr. 1998;68(2 suppl):495S–498S.

Black

. Zinc deficiency and child development. Am J Clin Nutr. 1998;68(2 suppl):464S–498S.

Ignaro

. Haem-dependent activation of guanylate cyclase and cyclic GMP formation by endogenous nitric oxide: a unique transduction mechanism for transcellular signaling. Pharmacol Toxicol. 1990;67(1):1–7.

Moncada

. The l-arginine: nitric oxide pathway. Acta Physiol Scand. 1992;145(3):201–227.

Bauersachs

Bouloumié

Fraccarollo

Busse

Ertl

. Endothelial dysfunction in chronic myocardial infarction despite increased vascular endothelial nitric oxide synthase and soluble guanylate cyclase expression: role of enhanced vascular superoxide production. Circulation. 1999;100(3):292–298.

Bouloumié

Bauersachs

Linz

. Endothelial dysfunction coincides with an enhanced nitric oxide synthase expression and superoxide anion production. Hypertension. 1997;30(4):934–941.

10.

Elnakish

Hassanain

L Janssen

Angelos

Khan

. Emerging role of oxidative stress in metabolic syndrome and cardiovascular diseases: important role of Rac/NADPH oxidase. J Pathol. 2013;231(3):290–300. doi:10.1002/path.4255.

11.

Inoue

Ramasamy

Fukai

Nerem

Harrison

. Shear stress modulates expression of Cu/Zn superoxide dismutase in human aortic endothelial cells. Circ Res. 1996;79(1):32–37.

12.

Kurihara

Yanagisawa

Sato

Tien

Wada

. Increased renal vascular resistance in zinc-deficient rats: role of nitric oxide and superoxide. Clin Exp Pharmacol Physiol. 2002;29(12):1096–1104.

13.

Naziroğlu

. New molecular mechanisms on the activation of TRPM2 channels by oxidative stress and ADP-ribose. Neurochem Res. 2007;32(11):1990–2001.

14.

Sato

Yanagisawa

Nojima

Tamura

Wada

. Zn deficiency aggravates hypertension in spontaneously hypertensive rats: possible role of Cu/Zn-superoxide dismutase. Clin Exp Hypertens. 2002;24(5):355–370.

15.

Mügge

Elwell

Peterson

Harrison

. Release of intact endothelium-derived relaxing factor depends on endothelial superoxide dismutase activity. Am J Physiol. 1991;260(2 pt 1):C219–C225.

16.

Omar

Cherry

Mortelliti

Burke-Wolin

Wolin

. Inhibition of coronary artery superoxide dismutase attenuates endothelium-dependent and -independent nitrovasodilator relaxation. Circ Res. 1991;69(3):601–608.

17.

Yanagisawa

Sato

Nodera

Wada

. Excessive zinc intake elevates systemic blood pressure levels in normotensive rats—potential role of superoxide-induced oxidative stress. J Hypertens. 2004;22(3):543–550.

18.

Kasai

Miyazaki

Takenaka

Yanagisawa

Suzuki

. Excessive zinc intake increases systemic blood pressure and reduces renal blood flow via kidney angiotensin II in rats. Biol Trace Elem Res. 2012;150(1-3):285–290.

19.

Yanagisawa

Miyakoshi

Kobayashi

. Long-term intake of a high zinc diet causes iron deficiency anemia accompanied by reticulocytosis and extra-medullary erythropoiesis. Toxicol Lett. 2009;191(1):15–19.

20.

Yanagisawa

Moridaira

Wada

. Zinc deficiency further increases the enhanced expression of endothelin-1 in glomeruli of the obstructed kidney. Kidney Int. 2000;58(2):575–586.

21.

Kawasaki

Suzuki

Yanagisawa

. Zinc deficiency enhances the induction of micronuclei and 8-hydroxy-2′-deoxyguanosine via superoxide radical in bone marrow of zinc-deficient rats. Biol Trace Elem Res. 2013;154(1):120–126. doi:10.1007/s12011-013-9706-8.

22.

Jing

Sun

Weng

Wang

. Effects of zinc levels on activities of gastrointestinal enzymes in growing rats. J Anim Physiol Anim Nutr (Berl). 2009;93(5):606–612.

23.

Yoshida

Ikeda

Nakazawa

. Suppression of 9L gliosarcoma growth by copper depletion with copper-deficient diet and d-penicillamine. J Neurooncol. 1993;17(2):91–97.

24.

Hoffman

Phyliky

Fleming

. Zinc-induced copper deficiency. Gastroenterology. 1988;94(2):508–512.

25.

Yanagisawa

Nodera

Umemori

Shimoguchi

Wada

. Role of angiotensin II, endothelin-1, and nitric oxide in HgCl₂-induced acute renal failure. Toxicol Appl Pharmacol. 1998;152(2):315–326.

26.

Yanagisawa

Nodera

Kurihara

Wada

. Altered expression of endothelin-1 and endothelial nitric oxide synthase in the juxtaglomerular apparatus of rats with HgCl₂-induced acute renal failure. Toxicol Lett. 1998;98(3):181–188.

27.

Naziroğlu

Dikici

Dursun

. Role of oxidative stress and Ca²⁺ signaling on molecular pathways of neuropathic pain in diabetes: focus on TRP channels. Neurochem Res. 2012;37(10):2065–2075.

28.

Taneja

Mandal

. Mineral Factors controlling essential hypertension—a study in the Chandigarh, India Population. Biol Trace Elem Res. 2007;120(1-3):61–73.

29.

Carpenter

Lam

Toney

Weintraub

Qin

. Zinc, copper, and blood pressure: human population studies. Med Sci Monit. 2013;19:1–8.

Zinc-Excess Intake Causes the Deterioration of Renal Function Accompanied by an Elevation in Systemic Blood Pressure Primarily Through Superoxide Radical-Induced Oxidative Stress

Abstract

Keywords

Introduction

Materials and Methods

Chemicals and Reagents

Dietary Regimen

Blood Collection and Tissue Preparations

Measurements of Systemic BP and RBF

Experiment 1

Experiment 2

Analysis of Inulin Clearance

Assay of Cu/Zn-SOD Activity

Assay of 8-OHdG Content

Statistical Analysis

Results

Discussion

Footnotes

Declaration of Conflicting Interests

Funding

References